重组人脑利钠肽治疗急性前壁心肌梗死介入术后患者的效果

Effects of recombinant human brain natriuretic peptide on patients with acute anterior myocardial infarction after interventional therapy

目的:观察重组人脑利钠肽治疗急性前壁心肌梗死介入术后患者的效果。方法:选取2020年1月至2022年1月该院收治的行急诊经皮冠状动脉介入术(PCI)治疗的110例急性前壁心肌梗死患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各55例。对照组采用常规药物治疗,观察组在对照组基础上采用重组人脑利钠肽治疗,比较两组临床疗效,治疗前、治疗72 h后心肌损伤标志物[心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、脑钠肽(BNP)]水平,心功能指标[左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)及左心室收缩末期容积(LVESV)]水平,以及治疗期间不良反应发生率。结果:观察组治疗总有效率为94.55%(52/55),显著高于对照组的80.00%(44/55),差异有统计学意义(P<0.05);治疗后,两组cTnI、CK-MB、BNP、LVESV水平均低于治疗前,且观察组低于对照组,两组LVEF、LVFS水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗基础上采用重组人脑利钠肽治疗急性前壁心肌梗死介入术后患者可提高治疗总有效率,改善心功能指标水平,降低心肌损伤标志物水平,效果优于单纯常规治疗。

Objective:To observe effects of recombinant human brain natriuretic peptide in the treatment of patients with acute anterior myocardial infarction after interventional therapy.Methods:A prospective study was conducted on 110 patients with acute anterior myocardial infarction who underwent emergency percutaneous coronary intervention(PCI)in this hospital from January 2020 to January 2022.They were divided into control group and observation group according to the random number table method,55 cases in each.The control group was treated with routine treatment,while the observation group was treated with recombinant human brain natriuretic peptide on the basis of the control group.The clinical efficacy,the levels of myocardial markers[cardiac troponin I(cTnI),creatine kinase isoenzyme(CK-MB),brain natriuretic peptide(BNP)]and the cardiac function index levels[left ventricular ejection fraction(LVEF),left ventricular fractional shortening(LVFS)and left ventricular end-systolic volume(LVESV)]before treatment and 72 h after the treatment,and incidence of adverse reactions during the treatment were compared between the two groups.Results:The total effective rate of treatment in the observation group was 94.55%(52/55),which was significantly higher than 80.00%(44/55)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of cTnI,CK-MB,BNP and LVESV in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of LVEF and LVFS in the two groups were higher than those before treatment,and those in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:On the basis of the routine treatment,recombinant human brain natriuretic peptide can improve the total effective rate of treatment,improve the levels of cardiac function indexes and reduce the levels of myocardial markers in the patients with acute anterior myocardial infarction after interventional therapy.Moreover,it is superior to single routine treatment.